Diana Perez

Prof. Diana Perez

Universidad Autónoma de Nuevo León

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez
Mariel Araceli Oyervides-MuñozMariel Araceli Oyervides-Muñoz
Mariel Araceli Oyervides-Muñoz
Antonio Ali Perez-MayaAntonio Ali Perez-Maya
Antonio Ali Perez-Maya
Celia N Sánchez-DomínguezCelia N Sánchez-Domínguez
Celia N Sánchez-Domínguez
ABAnais Berlanga
Anais Berlanga
VICTOR TREVINOVICTOR TREVINO
VICTOR TREVINO
Human papillomavirus (HPV) DNA integration is a crucial event in cervical carcinogenesis. However, scarce studies have focused on studying HPV integration (HPVint) in early-stage cervical lesions. Using HPV capture followed by sequencing, we investigated HPVint in pre-tumor cervical lesions. Employing a novel pipeline, we analyzed reads containing direct evidence of the integration breakpoint. We observed multiple HPV infections in most of the samples (92%) with a median integration rate of 0.06% relative to HPV mapped reads corresponding to two or more sequence breakages. Unlike cancer studies, most integrations events were unique (supported by one read), consistent with the lack of clonal selection. Congruent to other studies, we found that breakpoints could occur, practically, in any part of the viral genome. We noted that L1 had a higher frequency of rupture integration (25%). Based on host genome integration frequencies, we found previously reported integration sites in cancer for genes like FHIT, CSMD1, and LRP1B and putatively many new ones such as those exemplified in CSMD3, ROBO2, and SETD3. Similar host integrations regions and genes were observed in diverse HPV types within many genes and even equivalent integration positions in different samples and HPV types. Interestingly, we noted an enrichment of integrations in most centromeres, suggesting a possible mechanism where HPV exploits this structural machinery to facilitate integration. Supported by previous findings, overall, our analysis provides novel information and insights about HPVint.

28 January 2023 in Genes
Verified
Journal Article
Open access
PDF file
Diana PerezDiana Perez
Diana Perez
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez
MNMaría Fernanda Noriega-Iriondo
María Fernanda Noriega-Iriondo
SFSonia María Flores-Moreno
Sonia María Flores-Moreno
MGManuel Ismael González-Geroniz
Manuel Ismael González-Geroniz
Carlos Horacio Burciaga-FloresCarlos Horacio Burciaga-Flores
Carlos Horacio Burciaga-Flores
Hereditary cancer syndromes (HCS) are genetic diseases with an increased risk of developing cancer. This research describes the implementation of a cancer prevention model, genetic counseling, and germline variants testing in an oncologic center in Mexico. A total of 315 patients received genetic counseling, genetic testing was offered, and 205 individuals were tested for HCS. In 6 years, 131 (63.90%) probands and 74 (36.09%) relatives were tested. Among the probands, we found that 85 (63.9%) had at least one germline variant. We identified founder mutations in BRCA1 and a novel variant in APC that led to the creation of an in-house detection process for the whole family. The most frequent syndrome was hereditary breast and ovarian cancer syndrome (HBOC) (41 cases with BRCA1 germline variants in most of the cases), followed by eight cases of hereditary non-polyposic cancer syndrome (HNPCC or Lynch syndrome) (with MLH1 as the primarily responsible gene), and other high cancer risk syndromes. Genetic counseling in HCS is still a global challenge. Multigene panels are an essential tool to detect the variants frequency. Our program has a high detection rate of probands with HCS and pathogenic variants (40%), compared with other reports that detect 10% in other populations.

22 March 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
Fernando Alcorta-NuñezFernando Alcorta-Nuñez
Fernando Alcorta-Nuñez
Diana PerezDiana Perez
Diana Perez
Carlos Horacio Burciaga-FloresCarlos Horacio Burciaga-Flores
Carlos Horacio Burciaga-Flores
MGMiguel A Garza
Miguel A Garza
MGMoisés González-Escamilla
Moisés González-Escamilla
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez
Neutralizing antibodies (NAs) are key immunological markers and are part of the humoral response of the adaptive immune system. NA assays determine the presence of functional antibodies to prevent SARS-CoV-2 infection. We performed a real-world evidence study to detect NAs that confer protection against SARS-CoV-2 after the application of five vaccines (Pfizer/BioNTech, AstraZeneca, Sinovac, Moderna, and CanSino) in the Mexican population. Side effects of COVID-19 vaccines and clinical and demographic factors associated with low immunogenicity were also evaluated. A total of 242 SARS-CoV-2-vaccinated subjects were recruited. Pfizer/BioNTech and Moderna proved the highest percentage of inhibition in a mono-vaccine scheme. Muscular pain, headache, and fatigue were the most common adverse events. None of the patients reported severe adverse events. We found an estimated contagion-free time of 207 (IQR: 182–231) and 187 (IQR: 184–189) days for Pfizer/BioNTech and CanSino in 12 cases in each group. On the basis of our results, we consider that the emerging vaccination strategy in Mexico is effective and safe.

15 January 2025 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
DADione Aguilar
Dione Aguilar
MGMaría Lourdes Garza-Rodríguez
María Lourdes Garza-Rodríguez
CMCarolina Elizabeth Muñiz-Garza
Carolina Elizabeth Muñiz-Garza
FNFernando Alcorta Nuñez
Fernando Alcorta Nuñez
CVCynthia Mayte Villarreal-Garza
Cynthia Mayte Villarreal-Garza
Carlos Horacio Burciaga-FloresCarlos Horacio Burciaga-Flores
Carlos Horacio Burciaga-Flores
Background: Hereditary predisposition to breast and ovarian cancer syndrome (HBOC) is a pathological condition with increased cancer risk, including breast (BC), ovarian cancer (OC), and others. HBOC pathogenesis is caused mainly by germline pathogenic variants (GPV) in BRCA1 and BRCA2 genes. However, other relevant genes are related to this syndrome diagnosis, prognosis, and treatment, including TP53, PALB2, CHEK2, ATM, etc. This study aimed to identify the prevalence of non-BRCA genes in HBOC patients of Northeast Mexico. Methods: This multicentric study included 1285 patients with HBOC diagnosis from four oncologic centers in northeast Mexico from 2016 to 2023. Genomic and clinical data were analyzed based on multi-gene panel results and electronic records of the medical geneticist consultation. For the data analysis of qualitative and quantitative variants, JASP statistical software (version 0.18.1) was used, taking p < 0.05 as a significant result. Results: We found that 32.7% of the patients had at least one GPV in non-BRCA genes. The five most frequent non-BRCA genes were CHEK2, PALB2, MUTYH, CDKN2A, and ATM. Among the group of non-BRCA genes, six are involved in the homologous repair pathway (HR), and three are related to DNA damage repair (DDR) pathways. In analyzing GPVs in molecular pathways, both have similar frequencies with no statistical difference for BC. Conclusion: Multi-gene testing implementation improves the detection of often overlooked genes related to HBOC pathogenesis and treatment. Non-BRCA GPVs in Northern Mexico correspond to one-third of the HBOC cases, including HR and DDR pathways genes that would be misdiagnosed if not tested. HR patient carriers are potential targets of iPARP therapies. The optimal approach to cancer treatment for non-BRCA mutation carriers warrants further investigation to develop newer therapies.

25 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
Diana PerezDiana Perez
Diana Perez
Carlos Horacio Burciaga-FloresCarlos Horacio Burciaga-Flores
Carlos Horacio Burciaga-Flores
Ximena Garcia MejíaXimena Garcia Mejía
Ximena Garcia Mejía
Fernando Alcorta-NuñezFernando Alcorta-Nuñez
Fernando Alcorta-Nuñez
Orlando Solis-CoronadoOrlando Solis-Coronado
Orlando Solis-Coronado
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez
Background: Bacterial vaginosis (BV) is considered the most common cause of vaginal discharge, which is related to several public health issues, such as an increased risk for sexually transmitted infections, pelvic inflammatory disease, pregnancy-related problems such as abortion, stillbirth or premature birth, and tubal factor infertility. BV is not considered an infection but an imbalance in the vaginal microbiota, characterized by a substitution of the normal Lactobacilli flora by anaerobe. Reducing resistance against infections by several mechanisms, including bacterial homeostasis, stabilization of acid pH, inhibition of pathogens adhesion by polyamine degradation, production of anti-inflammatory molecules, surfactants, and antimicrobial substances like hydrogen peroxide, acids, and bacteriocins. Approximately half of women with BV can experience symptoms, which mainly include vaginal malodor, fishy discharge, stinging sensation, and increased vaginal pH. The treatment of BV is based primarily on promoting Lactobacilli restoration and eliminating dangerous microbiota with antibiotic therapy. However, there is a high rate of recurrence and relapse. Objective: Based on the current literature, this review aims to propose a list of ten BV hallmarks: dysbiosis, inflammation, apoptosis, pH basification, mucosal barrier integrity, pathway activation, epithelial damage, genomic instability, oxidative stress (OS), and metabolic reconfiguration. Conclusions: Understanding the causes of BV and the pathogenicity mechanisms is critical for preventing and improving the current therapeutic management of patients.

14 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Hugo L. Gallardo-BlancoHugo L. Gallardo-Blanco
Hugo L. Gallardo-Blanco
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez
Diana PerezDiana Perez
Diana Perez
Carlos Horacio Burciaga-FloresCarlos Horacio Burciaga-Flores
Carlos Horacio Burciaga-Flores
VSVictor Michael Salinas-Torres
Victor Michael Salinas-Torres
Celia N Sánchez-DomínguezCelia N Sánchez-Domínguez
Celia N Sánchez-Domínguez
Background: Breast cancer (BC), one of the most common cancers, has increased in Mexico during the past decade, along with other chronic and metabolic diseases. Methods: Herein, we analyzed 121 SNPs (85 SNPs related to BC and/or glucose-associated metabolic pathways and 36 SNP classified as ancestry markers) in 92 confirmed BC cases and 126 unaffected BC women from Northeastern Mexico. The relationship of these 121 SNPs with BC, considering BMI, menopause status, and age as cofactors, was explored using a gene–environment (G × E) interaction multi-locus model. Results: Twelve gene variants were significantly associated with BC: three located in exome (rs3856806 PPARG, rs12792229 MMP8, and rs5218 KCNJ11-ABCC8), and nine in non-coding regions, which are involved in accelerated decay of the mRNA transcripts, regulatory regions, and flanking regions (rs3917542 PON1; rs3750804 and rs3750805 TCF7L2; rs1121980 and rs3751812 FTO; rs12946618 RPTOR; rs2833483 SCAF4; rs11652805 AMZ2P1-GNA13; and rs1800955 SCT-DEAF1-DRD4). Conclusions: This study identified an association between BC and menopause, age (above 45), obesity, and overweight status with gene variants implicated in diabetes mellitus, obesity, insulin resistance, inflammation, and remodeling of the extracellular matrix.